Dr. Jeongyeon Mun | Molecular Biology | Best Researcher Award

Columbia University Medical Center | South Korea

Jeong-Yeon Mun is a highly productive researcher whose scientific contributions demonstrate growing global impact, supported by 454 citations recorded in her publication list. Her Google Scholar profile shows an h-index of 17 and 19 peer-reviewed documents, reflecting a consistent record of influential research across cancer genomics, tumor microenvironment biology, and therapeutic resistance mechanisms. Mun’s work spans a diverse collection of studies published in high-visibility journals, where she has contributed as both first author and co-author on investigations addressing critical topics such as glioblastoma metabolism, chemoresistance in bladder cancer, molecular subtype identification, immune regulation, and biomarker discovery. Her research also extends into experimental oncology, employing advanced genomic, metabolic, and molecular techniques to uncover pathways that shape cancer progression and response to therapy. In addition to her publications, she is credited with multiple patents related to diagnostic biomarkers and genetic typing technologies, demonstrating translational relevance beyond academic settings. Mun’s growing citation impact underscores her role in shaping contemporary cancer biology, while her multidisciplinary expertise continues to support significant advancements in understanding tumor behavior, therapeutic vulnerabilities, and molecular disease mechanisms

Featured Publications

Mun, J.-Y., Shu, C., Gao, Q., Akman, H. O., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. CDK12 regulates cellular metabolism to promote therapy resistance in glioblastoma. Cancer Research, 85(8_Supplement_1), 5395–5395.

Jeong, M.-S., Baek, S.-W., Yang, G.-E., Mun, J.-Y., Kim, J.-A., Kim, T.-N., Nam, J.-K., Choi, Y.-H., Lee, J.-S., Chu, I.-S., & Leem, S.-H. Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters, 610, 217339.

Leem, S.-H., Mun, J.-Y., Jeong, M.-S., & Kim, M.-H., Yang, G.-E.  Novel biomarker for diagnosing and predicting metastasis or prognosis of various cancers, and use (U.S. Patent Application No. 18/573,338).

Nguyen, T. T. T., Gao, Q., Mun, J.-Y., Zhu, Z., Shu, C., Naim, A., Rogava, M., Izar, B., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. Suppressing PD-L1 expression via AURKA kinase inhibition enhances natural killer cell-mediated cytotoxicity against glioblastoma. Cells, 13(13), 1155.

Jeongyeon Mun | Molecular Biology | Best Researcher Award

You May Also Like